#	Pagina
attuale pagina	/open-h2020/projects/207467/index.html

Opendata, web and dolomites

MagnaPharm SIGNED

Magnetic Control of Polymorphism in Pharmaceutical Compounds

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MagnaPharm project word cloud

Explore the words cloud of the MagnaPharm project. It provides you a very rough idea of what is the project "MagnaPharm" about.

representative 2017 multidisciplinary carbamazepine characterisations energy companies crystal crystallographic world cutting organic guided fetopen drugs drug innovation initially drive astrazeneca worth initial magnapharm billion pharmaceuticals pharmaceutical 12 polymorph theoretical form controllably centred effort international pharmaceutically worldwide almost responsible truly paradigm shifting sales 2016 profound lowest edge direct synthetic initiates indomethacin stages hence spectroscopic synthesizing underpinned desired solid compounds drawing profile 18 molecules processable society crystallizing coronene magnetic effect polymorphism prospect discovery hampered transformative

Project "MagnaPharm" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITY OF BRISTOL Organization address address: BEACON HOUSE QUEENS ROAD city: BRISTOL postcode: BS8 1QU website: www.bristol.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.magnapharm.com
Total cost	2˙886˙323 €
EC max contribution	2˙886˙323 € (100%)
Programme	1. H2020-EU.1.2.1. (FET Open)
Code Call	H2020-FETOPEN-1-2016-2017
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITY OF BRISTOL UNIVERSITY OF BRISTOL Organization address address: BEACON HOUSE QUEENS ROAD city: BRISTOL postcode: BS8 1QU website: www.bristol.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BRISTOL)	coordinator	1˙195˙677.00
2	UNIVERSITY COLLEGE LONDON UNIVERSITY COLLEGE LONDON Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	775˙673.00
3	UNIVERSITY OF LIMERICK UNIVERSITY OF LIMERICK Organization address address: NATIONAL TECHNOLOGICAL PARK, PLASSEY city: LIMERICK postcode: - website: www.ul.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (LIMERICK)	participant	554˙941.00
4	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	360˙031.00

Map

Project objective

This H2020-FETOPEN-2016-2017 proposal initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields. The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds, and hence on society.

It is proposed that MagnaPharm will drive forward innovation in pharmaceuticals by exploiting our new discovery that the polymorph and properties of carbamazepine, indomethacin and coronene can be controlled through the application of magnetic fields. We will apply our method to a range of pharmaceutical compounds, as guided by our project partner AstraZeneca, one of the largest pharmaceutical companies in the world. We will initially target 12 of the most high-profile, high-worth generic drugs with the aim of controllably synthesizing the desired polymorph of each (the lowest-energy polymorph and/or most processable form with desired properties). We aim for this goal via an international multidisciplinary approach centred around our discovery, underpinned by the development of a profound theoretical understanding of the effects of magnetic fields on organic crystal growth, that will direct the synthetic effort, all drawing on results from cutting edge spectroscopic and crystallographic characterisations.

With the 12 representative generic drug molecules targeted in the initial stages of MagnaPharm responsible for €18 billion of sales per year worldwide, and the development of many new pharmaceuticals being hampered by solid form issues, control over the production of the most pharmaceutically desired crystal is a truly paradigm-shifting prospect.

Deliverables

List of deliverables.
Technical Action Check Meeting	Other	2020-02-17 15:51:30
Produce initial report	Documents, reports	2020-02-17 15:51:30
Mid-Term Project Management Report	Documents, reports	2020-02-17 15:51:30
Crystallography data from the synthesis and characterisation of pharmaceutical targets under fields of 1 T to 37 T, being passed to WP2 for refinement of modelling	Documents, reports	2020-02-17 15:51:30
Annual report â€“ Year 1	Documents, reports	2020-02-17 15:51:30
Data Management Plan	Open Research Data Pilot	2020-02-17 15:51:30
MagnaPharm website live online	Websites, patent fillings, videos etc.	2020-02-17 15:51:30
Scientific Action Check Meeting 1	Other	2020-02-17 15:51:30
Dissemination and Exploitation Plan	Documents, reports	2020-02-17 15:51:30
Open Day/workshop	Other	2020-02-17 15:51:30

Take a look to the deliverables list in detail: detailed list of MagnaPharm deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2020	Rui Guo, M. Nadia Uddin, Louise S. Price, Sarah L. Price Calculation of Diamagnetic Susceptibility Tensors of Organic Crystals: From Coronene to Pharmaceutical Polymorphs published pages: , ISSN: 1089-5639, DOI: 10.1021/acs.jpca.9b07104	The Journal of Physical Chemistry A	2020-02-19
2020	Jennifer Cookman, Victoria Hamilton, Louise S. Price, Simon R. Hall, Ursel Bangert Visualising early-stage liquid phase organic crystal growth via liquid cell electron microscopy published pages: , ISSN: 2040-3364, DOI: 10.1039/c9nr08126g	Nanoscale	2020-02-19
2020	Stephen G. Sweeting, Charlie L. Hall, Jason Potticary, Natalie E. Pridmore, Stephen D. Warren, Matthew E. Cremeens, Gemma D. D\'Ambruoso, Masaomi Matsumoto, Simon R. Hall The solubility and stability of heterocyclic chalcones compared with trans -chalcone published pages: 13-17, ISSN: 2052-5206, DOI: 10.1107/s2052520619015907	Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials 76/1	2020-02-17
2018	Paolo Lucaioli, Elisa Nauha, Ilaria Gimondi, Louise S. Price, Rui Guo, Luca Iuzzolino, Ishwar Singh, Matteo Salvalaglio, Sarah L. Price, Nicholas Blagden Serendipitous isolation of a disappearing conformational polymorph of succinic acid challenges computational polymorph prediction published pages: 3971-3977, ISSN: 1466-8033, DOI: 10.1039/c8ce00625c	CrystEngComm 20/28	2020-02-17
2018	Sarah L. Price Control and prediction of the organic solid state: a challenge to theory and experiment published pages: 20180351, ISSN: 1364-5021, DOI: 10.1098/rspa.2018.0351	Proceedings of the Royal Society A: Mathematical, Physical and Engineering Science 474/2217	2020-02-17
2018	Hall, Charlie L. Potticary, Jason Sparkes, Hazel A. Pridmore, Natalie E. Hall, Simon R. Lamotrigine ethanol monosolvate published pages: 678-681, ISSN: 2056-9890, DOI:	Acta Crystallographica Section E Volume 74, Part 5, May 2018	2020-02-17
2017	Jan Gerit Brandenburg, Jason Potticary, Hazel A. Sparkes, Sarah L. Price, Simon R. Hall Thermal Expansion of Carbamazepine: Systematic Crystallographic Measurements Challenge Quantum Chemical Calculations published pages: 4319-4324, ISSN: 1948-7185, DOI: 10.1021/acs.jpclett.7b01944	The Journal of Physical Chemistry Letters 2017, 8	2020-02-17
2018	Jason Potticary, Michael P. Avery, Doug Mills, Simon R. Hall DONALD: A 2.5 T wide sample space permanent magnet published pages: , ISSN: 2468-0672, DOI: 10.1016/j.ohx.2018.01.002	HardwareX	2020-02-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGNAPHARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGNAPHARM" are provided by the European Opendata Portal: CORDIS opendata.